Staphylococcus haemolyticus superinfection of legionella pneumonia during infliximab therapy

Abstract

We present the case of a 42-year-old man affected by psoriasis with Staphylococcus Haemolyticus superin-fection of Legionella pneumonia during infliximab therapy. The introduction of compounds that block TNF-α has yielded great benefits for patients affected by selected autoimmune diseases that fail to respond to classic anti-inflammatory agents, but, on the other hand, has led to an increased susceptibility to infec-tions, in particular of those caused by intracellular pathogens, such as L. Pneumophila. Emerging evi-dence suggests that legionellosis can be complicated by superinfection with other agents, including sap-rophytic microorganisms, among which coagulase- negative staphylococci. To our knowledge, this is the first report of systemic legionellosis with superinfec-tion by S. Haemolyticus, an emerging nosocomial multi-resistant pathogen that commonly causes sep-ticemia, osteomyelitis or endocarditis, but has not so far been associated with necrotizing pneumonia. De-spite the optimal antimicrobial therapy for Staphylo-coccus spp. pneumonia is still controversial, evidence suggests that in patients with confirmed positivity for methicillin resistant strains, particularly if sensitivity to vancomycin is suboptimal, linezolid should be the first choice therapy, being superior to vancomycin and teicoplanin.

Share and Cite:

Porzio, M. , Valenti, L. , Bignamini, D. , Ricchini, F. , Palleschi, A. , Tarsia, P. and Fargion, S. (2011) Staphylococcus haemolyticus superinfection of legionella pneumonia during infliximab therapy. Open Journal of Internal Medicine, 1, 6-8. doi: 10.4236/ojim.2011.11003.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Carratala J, Garcia-Vidal C. (2010) An update on Legionella. Curr Opin Infect Dis, 23, 152-157.
[2] Weinblatt ME, Abbott GF, Koreishi AF. (2009) Case records of the Massachusetts General Hospital. Case 13- 2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung. N Engl J Med, 360, 1770- 1779.
[3] Tubach F, Ravaud P, Salmon-Ceron D, et al (2006) Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis, 43, 95-100.
[4] Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 54, 2368-2376.
[5] Froggatt JW, Johnston JL, Galetto DW, Archer GL (1989) Antimicrobial resistance in nosocomial isolates of Stap- hylococcus haemolyticus. Antimicrob Agents Chemother, 33, 460-466.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.